Vascular endothelial growth factor (VEGF) plays a pivotal role in tumor growth, invasion, and metastasis by promoting tumor angiogenesis. [1] [2] [3] Inhibition of VEGF signaling pathway has become a major approach in current cancer therapeutics. 3, 4 Bevacizumab (Avastin; Genentech, South San Francisco, CA), a humanized monoclonal antibody that inhibits the activity of VEGF, was the first biological agent of this class that has shown efficacy for the treatment of metastatic colorectal cancer (CRC). [5] [6] [7] [8] [9] Currently, it has been approved for the treatment of many other types of cancer, including non-small-cell lung cancer (NSCLC), breast cancer, renal cell carcinoma, and glioblastoma multiforme. [10] [11] [12] [13] [14] [15] [16] [17] [18] Bevacizumab significantly increased the risk of hypertension in cancer patients, as shown by our meta-analysis based on seven randomized-controlled clinical trials (RCTs). 19 We demonstrated that relative risks (RRs) of all-grade hypertension for patients administered with bevacizumab at 2.5 and 5.0 mg/kg/week were 3.0 (95% confidence interval (CI): 2.2-4.2; P < 0.001) and 7.5 (95% CI: 4.2-13.4; P < 0.001), respectively. Bevacizumab has also been shown to significantly increase the risk of arterial thromboembolic events in comparison with controls. 20 In addition, the use of bevacizumab has been linked to the development of reversible posterior leukoencephalopathy, a clinical event characterized by acute hypertension, headache, seizures, and visual disturbances. 21 Interestingly, hypertension as an on-target effect of bevacizumab may be correlated with better tumor response to antineoplastic treatment in patients with advanced CRC. 22 Severe hypertension including hypertensive crisis may cause significant cardiovascular damage with a possible life-threatening 
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Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis
Background Hypertension is associated with the use of bevacizumab, an angiogenesis inhibitor widely used in cancer therapy. Currently, the risk of severe hypertension associated with bevacizumab is unclear. We performed a systematic review and meta-analysis of published randomized-controlled clinical trials (RCTs) to assess the risk of highgrade hypertension in cancer patients treated with bevacizumab.
Methods
Databases from PUBMED, the Web of Science, and abstracts presented at the american Society of Clinical Oncology conferences until May 2009 were searched to identify relevant studies. Eligible studies included prospective RCTs in which bevacizumab was directly compared with controls in cancer patients receiving concurrent antineoplastic therapy. Summary incidence, relative risk (RR), and 95% confidence interval (CI) were calculated employing a fixed-or random-effects model based upon the heterogeneity of the included studies. results a total of 12,656 patients with a variety of tumors from 20 studies were included for the analysis. The incidence of all-grade hypertension in patients receiving bevacizumab was 23.6% (95% CI: 20.5-27.1) with 7.9% (95% CI: 6.1-10.2) being high-grade (grade 3 or 4). Patients treated with bevacizumab had a significantly increased risk of developing high-grade hypertension with an RR of 5.28 (95% CI: 4.15-6.71, P < 0.001) in comparison with controls. Even though not statistically significant, there was a trend suggesting that bevacizumab may increase the risk of hypertensive crisis (grade 4) with an RR of 3.16 (95% CI: 0.91-10.90). The increased risk of highgrade hypertension was observed in patients receiving bevacizumab at 2.5 mg/kg/week (RR = 4.78, 95% CI: 3.59-6.36) as well as 5 mg/ kg/week (RR = 5.39, 95% CI: 3.68-7.90). The risk of high-grade hypertension may vary with tumor types, with RRs ranging from 2. 49 consequence, and limit the use of bevacizumab. The incidences of high-grade (grade 3-4) hypertension in patients receiving bevacizumab varied substantially among clinical trials, ranging from 1.8 to 22.0% (refs. 14,23) . However, factors underlying the variation of high-grade hypertension have not been defined. In addition, the contribution of bevacizumab to developing high-grade hypertension is not clear. Because an individual trial may be limited in patient number and tumor type, we conducted a systematic review of published RCTs, and combined relevant studies for a meta-analysis to evaluate the overall risk of high-grade hypertension associated with bevacizumab.
Data source. An independent review of citations from PUBMED from January 1966 to May, 2009 was conducted. Keywords included in our search were "bevacizumab", "Avastin", "cancer", and was limited to "randomized controlled clinical trials". The search strategy also used text terms such as "hypertension", "angiogenesis", and "VEGF" to identify relevant information. Abstracts and virtual meeting presentations containing the term "bevacizumab" or "Avastin" from the American Society of Clinical Oncology conferences (http://www.asco.org/ASCO) between January 2000 and May 2009 were also referenced to identify relevant clinical trials. An independent search using the citation database Web of Science (developed by the institute for Scientific Information) was also performed to ensure that no clinical trials were overlooked. We examined each publication, and only the most recent or complete report of clinical trial was incorporated when duplicate publications were found. Efforts were made to contact investigators and the manufacturer of bevacizumab when relevant data were unclear. Finally, the updated manufacturer's package insert of bevacizumab was also reviewed to identify pertinent information. 10 Study selection. The goal of our study was to assess the contribution of bevacizumab to the development of high-grade hypertension in cancer patients; thus, only those RCTs with a direct comparison between bevacizumab and controls were incorporated for our analysis. Phase I trials and single-arm phase II trials were omitted from analysis due to the lack of controls. Clinical trials that met the following criteria were included in the meta-analysis: (i) prospective phase II or III trials involving cancer patients; (ii) random assignment of participants to bevacizumab treatment or control (placebo or best supportive care) in addition to concurrent therapy using a chemotherapeutic agent or a biological agent; and (iii) available data including event or incidence of hypertension and sample size. Quality was assessed using criteria including adequate blinding of randomization, completeness of follow-up, and objectivity of outcome measurements as previously described. 24 Data extraction and clinical endpoints. Data extraction was performed based upon patient characteristics, treatment information, results, and follow-up from these selected trials. Incidences or events of all-grade and high-grade hypertension and sample sizes were extracted from the safety profile in each trial. Independent data extraction was executed by three reviewers (V.R., B.P., and S.W.). Any discrepancies between reviewers were resolved by consensus. Hypertension events in these studies were assessed, and recorded according to versions 1, 2, or 3 of the National Cancer Institute's Common Terminology Criteria (NCI-CTC) for Adverse Events, 25 which have been widely used in cancer clinical trials. These versions are quite similar in grading hypertension events (see Table 1 for detail).
Statistical analysis. All statistical analyses were performed using the version 2 of the Comprehensive Meta-Analysis Program (Biostat, Englewood, NJ). 26 For the calculation of incidence, the number of patients with hypertension (both high-grade and all-grade) and the number of patients receiving bevacizumab were extracted from the selected clinical trials; the proportion of patients with hypertension and 95% exact CI were derived for each study. For the calculation of RR, patients assigned to bevacizumab were compared only with those assigned to control treatment in the same trial. To explore a dose-effect relationship, bevacizumab therapy was further divided into low-dose (2.5, 5, or 7.5 mg/kg/schedule, which is equivalent to a weekly dose of 2.5 mg/kg) and high-dose (10 or 15 mg/kg/dose/schedule, which is equivalent to a weekly dose of 5 mg/dose). The designation of low vs. high dose is relatively arbitrary. We previously have shown that all-grade hypertension may be dose-dependent. 19 For meta-analysis, both fixed-effects model (weighted with inverse variance) and random-effects model were considered. 27 For each meta-analysis, the Cochran's Q statistic and I 2 score were first calculated to assess the heterogeneity among the proportions of the included trials. 28 For the P value of Cochran's Q statistic <0.1, the assumption of homogeneity was deemed invalid, and a random-effects model was reported. The causes of heterogeneity were also explored in this context. Otherwise, results from the fixed-effects model were reported. A two-tailed P value <0.05 was judged as statistically significant. We used the Begg's and Egger's tests to determine the presence of publication bias regarding primary endpoint (RR of high-grade hypertension). 29, 30 A two-tailed P value of <0.05 was considered statistically significant.
results search results
Our literature search yielded 380 potentially relevant clinical studies on bevacizumab. After excluding review articles, phase I studies, single-arm phase II studies, case reports, metaanalysis, observational studies, studies in which both arms received bevacizumab, a total of 20 RCTs were selected for the purpose of analysis (Figure 1) . These trials include 6 phase II and 14 phase III studies, and their characteristics including enrolled number, number for analysis, follow-up time, underlying malignancies, concurrent treatment, bevacizumab dosing, and NCI-CTC versions are listed in Table 2 .
study quality
Randomized treatment allocation sequences were generated in all trials. Six trials were double-blinded and placebocontrolled, 11, 14, 15, 18, 23, 31 five other trials had placebo as controls, 8, 9, 13, 32, 33 and the rest of the trials had active treatment control. Hypertension was assessed and recorded according to National cancer Institute's common toxicity criteria version 1, 2, or 3. Version 1 was used in two clinical trials; 9,13 version 2 was used in eight trials; 5, 7, 8, 16, 17, [33] [34] [35] version 3 was used in six trials; 11, 18, 31, 32, 36, 37 and the rest of the trials did not specify. The quality of all the trials was acceptable.
Publication bias
No publication bias was detected for the primary endpoint of this study (RR of high-grade hypertension) by Begg's test (P = 0.21) and Egger's test (P = 0.24).
Patients
A total of 12,656 patients from 20 phase II and phase III clinical trials (bevacizumab: 6754; controls: 5902) were included for analysis. Hypertension was not listed as a baseline characteristic in any of these patients. The baseline Eastern Cooperative Oncology Group (ECOG) status for most of the patients was between 0 and 1. Patients were required to have adequate hepatic, renal, and hematologic function. The exclusion criteria for these studies included the following conditions: significant cardiovascular disease, PVD, uncontrolled HTN, serious nonhealing wounds, major surgery within previous 28 days, pre-existing bleeding diathesis, brain metastasis, regularly used aspirin (>325 mg/day) or nonsteroidal antiinflammatory drugs, pregnant or lactating women, taking oral or parental anticoagulants with the exception of prophylactic anticoagulants to maintain patency of vascular device access. Underlying malignancies included CRC (seven studies), NSCLC (four studies), breast cancer (three studies), pancreatic cancer (three studies), renal cell cancer (three studies), The incidence and RR were calculated from the trials included in this study by meta-analysis as described in the "Methods" section. CI, confidence interval; N/A: not applicable; NSCLC, non-small-cell lung carcinoma; RR, relative risk. Figure 2 | Relative risk (RR) of high-grade hypertension associated with bevacizumab vs. controls. Overall summary RR of high-grade hypertension was calculated using a fixed-effects or random-effects model. RR for each study is displayed numerically on the left and graphically on the right. Total events and sample sizes are also displayed for each study. For study name, the first author's name was used to represent each trial. If the same first author was involved in two trials, then the publication year was also included to identify the trial. For each trial the position of the square denoted the value of RR, horizontal lines represent 95% CI, and diamond plot represents overall results of the included trials. CI, confidence interval.
and malignant mesothelioma (one study). In all trials, patients were randomly assigned to either a control or bevacizumab group, with five three-arm studies each having two bevacizumab treatment groups, in which patients received different dose levels or combinations.
risk of all-grade hypertension
Eleven RCTs included data pertaining to all-grade hypertension, and were analyzed for the incidence of all-grade hypertension. A total of 3,679 patients with different solid tumor types were available for analysis. Among the patients who were administered with bevacizumab, meta-analysis revealed that the summary incidence of all-grade hypertension was 23.6% (95% CI: 20.5-27.1), using a random-effects model. We also calculated the RR of all-grade hypertension from these RCTs. Using a fixed-effects model, the summary RR was determined to be 3.02 (95% CI: 2.24-4.07, P < 0.001) in comparison with controls, suggesting a significantly increased risk of all-grade hypertension with bevacizumab.
incidence of high-grade hypertension
All 20 studies reported incidences of high-grade (combined grade III and IV) hypertension, with the highest incidence (22.0%) observed in the malignant mesothelioma trial, 14 and the lowest incidence (1.8%) seen in a breast cancer trial. 23 A total of 6,754 patients from these studies received the treatment of bevacizumab in combination with chemotherapy or biological agents. Using a random-effects model, the summary incidence of high-grade hypertension was 7.9% (95% CI: 6.1-10.2), as shown in Table 3 .
Only five studies reported grade 3 and 4 hypertension separately. 7, 16, 17, 36, 37 The incidence of grade 4 hypertension (hypertensive crisis) was 0.5% (95% CI: 0.3-0.8) among 2,771 patients receiving bevacizumab. No grade 5 hypertension (death) was reported in all of these trials.
rr of high-grade hypertension
The observed incidence of high-grade hypertension in patients receiving bevacizumab may be attributable to risk factors such as obesity, diabetes, medications, diet, or other underlying factors. In order to assess the role of bevacizumab on the development of high-grade hypertension, and to exclude the influence of confounding factors, we calculated the overall RR of highgrade hypertension from these trials in which patients treated with bevacizumab were compared with controls in combination with concurrent antineoplastic treatment. Based on 20 RCTs including 12,656 patients, the summary RR of bevacizumab vs. controls was 5.28 (95% CI: 4.15-6.71, P < 0.001) using a fixed-effects model (Figure 2) , suggesting that bevacizumab significantly increased the risk of high-grade hypertension as high as 5.28-fold in comparison with controls.
We also determined the role of bevacizumab in hypertensive crisis. Based on five RCTs, 7, 16, 17, 36, 37 the RR of bevacizumab vs. controls for grade IV hypertension was 3.16 (95% CI: 0.91-10.90; P = 0.069), suggesting a trend that bevacizumab may significantly increased the risk of hypertensive crisis.
high-grade hypertension and bevacizumab dose
We explored the relationship between the dose of bevacizumab and the risk of developing high-grade hypertension. From 10 trials containing 7,208 patients (bevacizumab 3,641, controls 3,567), low-dose bevacizumab administration (2.5 mg/ kg/week) was associated with a significantly increased risk of high-grade hypertension with an RR of 4.78 (95% CI: 3.59-6.36, P < 0.001). Similarly, from 14 trials consisting of 6,096 patients (bevacizumab 3,122, controls 2,974), the high-dose bevacizumab administration (5.0 mg/kg/week) was associated with a significantly increased risk of high-grade hypertension (RR: 5.39; 95% CI: 3.68-7.90, P < 0.001).
risk of high-grade hypertension and tumor type
The risk of bevacizumab-associated high-grade hypertension may be affected by underlying tumor and its related treatment. In order to understand the risk of high-grade hypertension in patients with different tumor types, we calculated incidence and RR according to tumor types using meta-analysis ( Table 3) . Incidences of high-grade hypertension ranged from 5.5% (95% CI: 2.2-12.7) in patients with pancreatic cancer to 22.6% (95% CI: 13.3-35.8) in patients with mesothelioma; RRs ranged from 2.49 (95% CI: 0.94-6.59) in mesothelioma to 14.80 (95% CI: 0.92-238.51) in patients with breast cancer. Bevacizumab significantly increased the risk of high-grade hypertension in patients with renal cancer (RR: 8.99; 95% CI: 2.72-29.72), NSCLC (RR: 7.06; 95% CI: 3.66-13.62), pancreatic cancer (RR: 5.52; 95% CI: 2.12-14.35), and CRC (RR: 5.24; 95 % CI: 3.89-7.05). Although the incidence of hypertension was increased in mesothelioma and breast cancer, the RRs in these diseases were not significantly increased.
risk of high-grade hypertension and clinical outcome
Because the development of grade 2 and 3 hypertension may predict clinical efficacy of bevacizumab treatment in CRC patients, 22 we thus explored the relationship between highgrade hypertension and clinical outcome such as progressionfree survival (PFS) or overall survival (OS) in these patients with a variety of tumors. Efficacy data from these studies showed that the benefit of bevacizumab treatment was related to tumor type. Bevacizumab significantly increased PFS and OS in patients with NSCLC and CRC, and significantly increased PFS in patients with breast cancer and renal cell cancer, but did not improve PFS or OS in patients with pancreatic cancer and malignant mesothelioma. On the other hand, the effect of bevacizumab on blood pressure was present in all tumor types and not limited to a particular type. To further understand this issue, we explored a correlation between high-grade hypertension and PFS or OS at study level. No significant correlation was found between RRs of high-grade hypertension and hazard ratios of PFS (R 2 = 0.0003, P > 0.05) among these studies. Similarly, we did not find any correlation between RRs of highgrade hypertension and OS (R 2 = 0.0005, P > 0.05). Therefore, high-grade hypertension may be not correlated with clinical outcome for bevacizumab-based treatment at study level.
discussion
Our study has demonstrated that bevacizumab is associated with a significantly increased risk of high-grade hypertension, with an incidence of 7.9% (95% CI: 6.1-10.2) and RR of 5.28 (95% CI: 4.15-6.71) in 12,656 patients with a variety of solid tumors from 20 RCTs. The clinical significance of severe hypertension is evident because of associated cardiovascular complications. Indeed, severe hypertension can require hospitalization or discontinuation of bevacizumab in up to 1.7% of patients; complications may include hypertensive encephalopathy, central nervous system hemorrhage, reversible posterior leukoencephalopathy, and congestive heart failure. 10 In addition, high-grade hypertension may lead to arterial thromboembolic events, which were significantly increased in cancer patients treated with bevacizumab. 20 Therefore, it is particularly important for all health-care providers and patients to recognize the risk, and to monitor and treat hypertension timely and appropriately.
In addition to bevacizumab, other angiogenesis inhibitors such as sunitinib and sorafenib, which block the activity of VEGF receptors, are also associated with high-grade hypertension. Based on our previous studies, the incidences of high-grade hypertension for sunitinib and sorafenib were 6.8% (95% CI: 5.3-8.8) and 5.7% (95% CI: 2.5-12.6), respectively, 38,39 as compared to 7.9% (95% CI: 6.1-10.2) for bevacizumab in this study. Thus, it appears that the absolute risk of high-grade hypertension induced by these angiogenesis inhibitors is remarkably similar.
Efforts are ongoing to understand the mechanism of hypertension associated with angiogenesis inhibitors. The binding of VEGF to its corresponding receptors can enhance microvascular permeability, initiate cell division and migration, and impede apoptosis and senescence. 40, 41 Inhibition of VEGF effect may cause decreased endothelial renewal capacity and increased apoptosis. 42, 43 In addition, it interferes with endothelial cell production of vasodilators such as nitrous oxide and prostacyclin, leading to vasoconstriction. 44, 45 Similar effects of VEGF antagonism in kidneys may contribute to the development of hypertension. Appropriate VEGF expression in endothelial cells and podocytes of kidneys maintains a normal glomerular structure and function. Disruption of the VEGF signaling pathway leads to inhibition of nitric oxide synthase, thereby reducing nitric oxide and prostacyclin synthesis. This in turn renders a vasoconstrictive effect and decreased sodium ion renal excretion, resulting in elevated blood pressure. In addition, hypertension may be related to vascular rarefaction, a functional decrease in the number of arterioles and capillaries generating an increase in peripheral vascular resistance. 46, 47 We also explored the relationship between bevacizumab dose and high-grade hypertension. Previously, we have reported that the high-dose administration of bevacizumab at 5 mg/kg/ week had more than doubled RR of the low-dose bevacizumab at 2.5 mg/kg/week (RR: 7.5 vs. 3.0). Here, we showed that RRs of high-grade hypertension were 4.78 (95% CI: 3.59-6.36) for the low dose, and 5.39 (95% CI: 3.68-7.90) for the high-dose of bevacizumab; thus, the difference between the high and low doses of bevacizumab for high-grade hypertension was not as evident as for all-grade hypertension. It is possible that our study may be limited in power to detect a small difference due to the much lower incidence of high-grade hypertension in comparison with all-grade hypertension. Alternatively, it can be speculated that the development of high-grade hypertension may have a distinct mechanism involving VEGF or its receptor polymorphism resulting in differential sensitivity to anti-VEGF effect of bevacizumab. This is consistent with the observation that a particular VEGF genotype was correlated with hypertension in patients with metastatic renal cell carcinoma undergoing the therapy of sunitinib. 48 Our study demonstrated that the risk of high-grade hypertension associated with bevacizumab varies among patients with different tumor type, with significantly increased risks observed in patients with renal cell carcinoma (RR: 8.99, 95% CI: 2.72-29.72), NSCLC (RR: 7.06; 95% CI: 3.66-13.62), pancreatic cancer (RR: 5.52; 95% CI: 2.12-14.35), and CRC (RR: 5.24, 95% CI: 3.89-7.05). The higher RR in patients with renal cell carcinoma can be secondary to decreased glomerular filtration because of nephrectomy commonly performed in these patients. 49 It is not clear whether a decreased GFR may reduce renal clearance and lead to a higher concentration of bevacizumab. Although it was not statistically significant, a particularly high RR of 14.80 (95% CI: 0.92-238.51) was found for patients with breast cancer. It is possible that breast cancer patients, who would receive a wide array of adjuvant therapies with known cardiovascular side effects, may be more prone to the anti-VEGF effect of bevacizumab. 50 Interestingly, the development of grade 2 and 3 hypertension was correlated with better disease control in advanced CRC patients undergoing bevacizumab-based therapy. 22 Thus, high-grade hypertension may be a biomarker predicting clinical activity of bevacizumab. At study level, we did not find any correlation between high-grade hypertension and PFS or OS. However, this does not exclude the possibility that a correlation might exist for all-grade hypertension or at patient level. Further prospective large trials with standard blood pressure measurement may be able to resolve this issue.
There are no specific guidelines for the treatment of bevacizumab-associated hypertension. The packet insert recommends permanently discontinuing bevacizumab in patients with hypertensive crisis or hypertensive encephalopathy, and temporarily suspending bevacizumab in patients with severe hypertension that is not controlled with medical management. 10 Blood pressure monitoring should be implemented after the initiation of bevacizumab. Lifestyle modification may be considered for patients with hypertension. No clear recommendation for an antihypertensive agent can be made because there is a lack of controlled studies addressing the subject. Medical treatment may comprise angiotensin-converting enzyme inhibitors, β-blockers, diuretics, and calcium-channel blockers. 12, 19, 51 Our study has several limitations. The findings described here are affected by the limitations of individual trials included in the analysis. These clinical trials may have underestimated the incidence of hypertension, which was defined as BP >150/100 mm Hg by NCI's Common toxicity criteria. The standard criteria according to JNC 7 for the diagnosis of hypertension as BP >140/90 mm Hg would identify more patients with hypertension. Other classification methods proposed by European Society of Hypertension may also better define blood pressure variation Second, these studies were conducted at various institutions across the country, and hence may contribute bias related to instruments, recording of blood pressure, different protocols followed by different institutions resulting in potential bias of reported incidences. The reported incidence of high-grade hypertension had significant heterogeneity among the included studies. Nevertheless, we have minimized its influence by using a random-effects model to calculate the overall incidence of high-grade hypertension. Despite these differences, RRs reported by all of the studies were remarkably nonheterogenous. Third, these studies were conducted at major academic institutions for patients with adequate major organ function, and may not reflect general patient population in the community or those patients with organ dysfunction. Therefore, conclusions from these studies may not be applied to general patient population in community or patients with organ dysfunction. Fourth, this is a meta-analysis at study level; therefore confounding variables at the patient level cannot be assessed properly and incorporated into the analysis. In addition, we were not able to find any meaningful correlation between high-grade hypertension and study level covariants such as follow-up duration, cancer types, bevacizumab dose, and number of subjects by logistic regression. Fifth, although we were not able to detect significant publication bias on the P values from Begg's and Egger's test, and also searched unpublished abstracts from ASCO conferences to reduce publication bias, it may not be sufficient to identify unpublished results to eliminate publication bias. Finally, even though our analysis showed that bevacizumab did not significantly increase the risk of hypertensive crisis (RR: 3.16; 95% CI: 0.91-10.90, P = 0.069), the conclusion may be limited by a small number of studies with available data for analysis.
In summary, our study has shown that the addition of bevacizumab to concurrent antineoplastic therapy significantly increased the risk of high-grade hypertension in cancer patients. The risk was associated with both low and high doses of bevacizumab, and may vary among patients with different tumors. It is important for physicians and patients to recognize the risk, and treat it adequately in order to prevent cardiovascular complications. Future studies are recommended to investigate risk reduction and to optimize bevacizumab-based therapy.
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